Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 28 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2016 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 New trial record